Clinical Trials Logo

Filter by:
NCT ID: NCT03773146 Completed - Clinical trials for Surveys and Questionnaires

Use of Airtime Structure to Improve Interactive Voice Response Surveys in Bangladesh and Uganda

Start date: March 26, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effect of three different airtime incentive structures on interactive voice response (IVR) survey cooperation, response, refusal and contact rates, as compared to a control group, in Bangladesh and Uganda.

NCT ID: NCT03772509 Completed - Clinical trials for Surveys and Questionnaires

Use of Introduction Mode to Improve Interactive Voice Response Surveys in Bangladesh and Tanzania

Start date: June 14, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effect of two different introduction modes on interactive voice response (IVR) survey cooperation, response, refusal, and contact rates, in Bangladesh and Tanzania.

NCT ID: NCT03772431 Completed - Clinical trials for Surveys and Questionnaires

Use of Narrative Voice and Introduction Content to Improve Interactive Voice Response Surveys in Bangladesh and Uganda

Start date: March 26, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effect of two different narrative voices (one male and one female) and two different introductions (one with informational content and the other with additional motivational content) on interactive voice response (IVR) survey cooperation, response, refusal, and contact rates, as compared to a control group (male, informational), in Bangladesh and Uganda.

NCT ID: NCT03768323 Completed - Clinical trials for Surveys and Questionnaires

Airtime Incentive Amounts to Improve Interactive Voice Response Surveys in Bangladesh and Uganda

Start date: March 26, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effect of two different airtime incentive amounts on interactive voice response (IVR) survey cooperation, response, refusal, and contact rates, as compared to control group, in Bangladesh and Uganda.

NCT ID: NCT03736161 Completed - Psoriatic Arthritis Clinical Trials

Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis

PsOLSET-BD
Start date: September 15, 2017
Phase: Phase 3
Study type: Interventional

Title Safety and Efficacy of Tofacitinib vs Methotrexate in the treatment of Psoriatic Arthritis- An Open Label Randomized single center study Psoriatic arthritis is defined as an inflammatory arthropathy associated with skin psoriasis and usually negative for rheumatoid factor. Till date, many NSAIDs, corticosteroids, DMARDs have been used, but the safety and efficacy issues demands more researches. The prevalence of PsA worldwide is about 1%-2% and among patients with psoriasis ranges from 7% to 42%. The pathogenesis of PsA involves many cytokines. Tofacitinib is an oral Janus Kinase (JAK) inhibitor with immunomodulatory and anti-inflammatory mechanism. It binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway which ultimately decreases the production of pro-inflammatory cytokines, and prevents both inflammatory response and the inflammation-induced damage. It has shown better efficacy in many diseases like Rheumatoid Arthritis, Axial spondyloarthropathies, Psoriasis, Psoriatic Arthritis, Alopecia areata, dry eye disease. This prospective, open label, randomized study will be conducted in inpatient and outpatient departments of Rheumatology, BSMMU, Dhaka, Bangladesh in 110 adult volunteers (>18 years) of both genders diagnosed as psoriatic arthritis. Patients will be divided equally into two groups, Group A will be put on Tofacitinib 5 mg twice daily and Group B will be put on Methotrexate weekly in increasing dose with maximum dose of 25 mg weekly. Groups will be divided on the basis of randomization by random number table. Patients with inadequate response to highest dose of MTX or Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 5 mg BD or Tofacitinib 10 mg BD respectively. The patients not eligible for therapy will not be included in the study. Patients will be followed up at 1, 3 and 6 months. Baseline characteristics will be monitored and recorded at 3 and 6 months. The clinical information of the study subjects will be recorded in a structured history, clinical examination and questionnaire. All subjects will be enrolled after having informed written consent. The participants will enjoy every right to participate or withdraw from the study at any point of time. Response to Tofacitinib will be expressed in mean, standard deviation and percentage. Ethical clearance will be taken from the Institutional Review Board (IRB) of BSMMU.

NCT ID: NCT03722004 Completed - Poliomyelitis Clinical Trials

Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study

mOPV1
Start date: December 18, 2018
Phase: Phase 4
Study type: Interventional

This is an open-label phase IV randomized clinical trial that will assess intestinal and humoral immunity among infants who receive a combination of monovalent oral poliovirus vaccine type 1 and fractional dose of inactivated poliovirus vaccine, monovalent oral poliovirus vaccine type 1 only, and bivalent oral poliovirus vaccine only.

NCT ID: NCT03721302 Completed - Neonatal SEPSIS Clinical Trials

NeoAMR Observational Study in Neonatal Sepsis

Start date: August 16, 2018
Phase:
Study type: Observational

Prospective, multinational, multicentre, observational cohort study of neonatal sepsis in partner institutions. The cohort study will be designed to evaluate health care utilization and current clinical practice and to assess risk factors for and outcomes of babies with neonatal sepsis (culture-negative and culture-positive).

NCT ID: NCT03719196 Completed - Presbyopia Clinical Trials

Reading Glass on Livelihoods and Quality of Life in Rural Bangladesh

Start date: April 30, 2017
Phase: N/A
Study type: Interventional

The issue of uncorrected Presbyopia is an emerging health and livelihoods problem in Bangladesh. Presbyopia is easily corrected with an appropriate pair of reading glasses. Non-governmental organizations and government agencies have been working in many emerging markets, including Bangladesh, to increase eyeglass coverage among low-income adults by introducing basic vision screening and the dispensing of reading glasses at the community level. While vision screening is typically considered a health intervention, the primary motivation of these organizations and government agencies is to correct blurry vision with the intention of improving adults' income earning potential. VisionSpring and BRAC (previously known as Bangladesh Rural Advancement Committee) are two such NGOs who are partnering to implement a "Reading Glasses for Improved Livelihoods" program. VisionSpring is a social enterprise with a mission to increase access to affordable eye care and glasses in low-income settings. BRAC is an international development organization dedicated to alleviating poverty by empowering the poor. VisionSpring and BRAC have initiated a Randomized Control Trial to assess the economic and social impact that reading glasses may have on individuals that earn less than $4 a day. The study hypothesizes that post-intervention, the adoption of reading glasses will increase productivity related to paid work, and will enhance the vision-related quality of life of adults with Presbyopia. This experimental trial is designed to test the aforementioned hypotheses. In March 2017 a census survey was conducted in 59 villages of adults aged ≥35 and ≤65 years old in order to identify individuals with uncorrected presbyopia who would be eligible for enrollment in the study intervention. Following household visual acuity screenings, study participants were selected for enrollment. Randomization was conducted at the household level. Based on the inclusion criteria, a total of 824 random households were surveyed at the baseline. Following completion of the baseline survey, in August 2017 the treatment group was given reading glasses free-of-cost. The endline survey will be conducted in March 2018, eight months from the baseline. Although some income-related outcomes may take more time to manifest, it is anticipated that the wearing of glasses precipitates changes in a relatively short time frame. The control group will receive reading glasses at the conclusion of the endline survey.

NCT ID: NCT03716804 Completed - Clinical trials for Antibiotic Resistant Infection

Establish the Relationship Between Shift in Prescribing Pattern and Associated Shift in Sensitivity Pattern of Causative Microbes in UTI Patients in a Closed Community

UTI
Start date: June 6, 2018
Phase: Phase 4
Study type: Interventional

To establish a relationship between changed prescribing pattern and associated shift in sensitivity trend of causative microbes in patients of uncomplicated urinary tract infection in a closed community

NCT ID: NCT03715790 Completed - Clinical trials for Acute Myocardial Infarction

Improve SCA Bridge Study

Start date: November 2, 2018
Phase:
Study type: Observational

The purpose of the Improve SCA Bridge study is to characterize the care pathway flow of post-acute myocardial infarction (MI) patients as a result of standard assessments of left ventricular ejection fraction (LVEF) in the acute phase (≤14 days post- acute MI) and chronic phase (≥40-90 days post-acute MI).